Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Takeda Pharmaceutical Co Ltd ( - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TAK
New York
2834
https://www.takeda.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Takeda Pharmaceutical Co Ltd (
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
- Apr 18th, 2024 11:00 pm
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
- Apr 8th, 2024 12:00 pm
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
- Apr 5th, 2024 10:30 pm
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
- Mar 27th, 2024 12:53 pm
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- Mar 26th, 2024 11:07 pm
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
- Mar 26th, 2024 12:00 pm
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
- Mar 25th, 2024 1:57 pm
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
- Mar 19th, 2024 4:20 pm
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- Mar 19th, 2024 10:30 am
Japan’s Stock Market Is Back, and It Isn’t Too Late to Buy
- Mar 14th, 2024 6:15 am
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
- Mar 13th, 2024 12:00 pm
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
- Mar 11th, 2024 4:00 pm
TAK or STVN: Which Is the Better Value Stock Right Now?
- Mar 11th, 2024 3:40 pm
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
- Mar 11th, 2024 1:40 pm
Alexandria (ARE) Announces Lease Extension at Kendall Square
- Mar 5th, 2024 4:55 pm
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
- Feb 27th, 2024 4:30 am
Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
- Feb 27th, 2024 4:30 am
Championing Rare Voices on Rare Disease Day
- Feb 26th, 2024 12:00 pm
11 Best Japanese Stocks To Buy In 2024
- Feb 24th, 2024 10:07 am
20 Fastest Growing Biotech Companies in the US
- Feb 23rd, 2024 10:43 am
Scroll